Literature DB >> 22147643

A comparison between complete immobilisation and protected active mobilisation in sensory nerve recovery following isolated digital nerve injury.

F P Henry1, R I Farkhad, F S Butt, M O'Shaughnessy, S T O'Sullivan.   

Abstract

Post-operative immobilisation following isolated digital nerve repair remains a controversial issue amongst the microsurgical community. Protocols differ from unit to unit and even, as evidenced in our unit, may differ from consultant to consultant. We undertook a retrospective review of 46 patients who underwent isolated digital nerve repair over a 6-month period. Follow-up ranged from 6 to 18 months. Twenty-four were managed with protected active mobilisation over a 4-week period while 22 were immobilised over the same period. Outcomes such as return to work, cold intolerance, two-point discrimination and temperature differentiation were used as indicators of clinical recovery. Our results showed that there was no significant difference noted in either clinical assessment of recovery or return to work following either post-operative protocol, suggesting that either regime may be adopted, tailored to the patient's needs and resources of the unit.

Entities:  

Mesh:

Year:  2011        PMID: 22147643     DOI: 10.1177/1753193411431208

Source DB:  PubMed          Journal:  J Hand Surg Eur Vol        ISSN: 0266-7681


  3 in total

1.  Prevalence of cold sensitivity in patients with hand pathology.

Authors:  Christine B Novak; Steven J McCabe
Journal:  Hand (N Y)       Date:  2015-06

2.  Postoperative mobilization regimens following digital nerve repair: a systematic review.

Authors:  Shehab Jabir; Fortune C Iwuagwu
Journal:  Eplasty       Date:  2014-01-17

3.  Influence of immobilization and sensory re-education on the sensory recovery after reconstruction of digital nerves with direct suture or muscle-in-vein conduits.

Authors:  Theodora Manoli; Jennifer Lynn Schiefer; Lukas Schulz; Thomas Fuchsberger; Hans-Eberhard Schaller
Journal:  Neural Regen Res       Date:  2016-02       Impact factor: 5.135

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.